Active-ingredient Dossier
Lamivudine
Active-ingredient Dossier for Lamivudine (nucleoside reverse transcriptase inhibitor). Australian brands, products, PBS listings, PBAC outcomes —…
- Brand: 3TC
- Brand: COMBIVIR
- Brand: DOVATO
- Brand: TRIUMEQ
- Brand: ZEFFIX
- Brand: ABACAVIR/LAMIVUDINE
- Therapeutic area: Infectious Disease
What is
Lamivudine Lamivudine is a nucleoside reverse transcriptase inhibitor.
Australian brands containing
Lamivudine — 3TC — ZEFFIX — DOVATO — TRIUMEQ — ABACAVIR/LAMIVUDINE — COMBIVIR — KIVEXA — LAMIVUDINE VIATRIS — LAMIVUDINE/ZIDOVUDINE — ZETLAM
Therapeutic areas
Lamivudine is registered in Infectious Disease, with 17 brands containing this ingredient on the ARTG.
Sponsor landscape
Lamivudine is marketed by five sponsors: ViiV Healthcare, Alphapharm, Sun Pharma, Arrotex Pharmaceuticals, and Lupin.
PBS and regulatory activity
Two brands containing lamivudine have PBS-listed items, with the latest PBS schedule date of 1 May 2026. PBS government expenditure was $55,151,218.06 in the 2017–18 financial year, based on 30,227 scripts. The latest PBAC outcome was recorded on 1 August 2019, and the latest AusPAR on 11 September 2019, with two brands having PBAC outcomes and two brands having AusPARs on record.